Cargando…

Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver

OBJECTIVE— Recent progress suggests that exenatide, a mimetic of glucagon-like peptide-1 (GLP-1), might lower glycemia independent of increased β-cell response or reduced gastrointestinal motility. We aimed to investigate whether exenatide stimulates glucose turnover directly in insulin-responsive t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Dan, Ionut, Viorica, Mooradian, Vahe, Stefanovski, Darko, Bergman, Richard N.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628608/
https://www.ncbi.nlm.nih.gov/pubmed/19011168
http://dx.doi.org/10.2337/db08-0875
_version_ 1782163708370223104
author Zheng, Dan
Ionut, Viorica
Mooradian, Vahe
Stefanovski, Darko
Bergman, Richard N.
author_facet Zheng, Dan
Ionut, Viorica
Mooradian, Vahe
Stefanovski, Darko
Bergman, Richard N.
author_sort Zheng, Dan
collection PubMed
description OBJECTIVE— Recent progress suggests that exenatide, a mimetic of glucagon-like peptide-1 (GLP-1), might lower glycemia independent of increased β-cell response or reduced gastrointestinal motility. We aimed to investigate whether exenatide stimulates glucose turnover directly in insulin-responsive tissues dependent or independent of insulinemia. RESEARCH DESIGN AND METHODS— An intraportal glucose infusion clamp was used in dogs to measure glucose turnover to encompass potent activation of the putative glucose/GLP-1 sensor in the porto-hepatic circulation with exenatide. The modified glucose clamp was performed in the presence of postprandial hyperinsulinemia and hyperglycemia with exenatide (20 μg) or saline injected at 0 min. Furthermore, the role of hyperglycemia versus hyperinsulinemia in exenatide-mediated glucose disposal was studied. RESULTS— With hyperinsulinemia and hyperglycemia, exenatide produced a significant increase in total glucose turnover by ∼30%, as indicated by portal glucose infusion rate (saline 15.9 ± 1.6 vs. exenatide 20.4 ± 2.1 mg · kg(−1) · min(−1), P < 0.001), resulting from increased whole-body glucose disposal (R(d), ∼20%) and increased net hepatic uptake of exogenous glucose (∼80%). Reducing systemic hyperglycemia to euglycemia, exenatide still increased total glucose turnover by ∼20% (saline 13.2 ± 1.9 vs. exenatide 15.6 ± 2.1 mg · kg(−1) · min(−1), P < 0.05) in the presence of hyperinsulinemia, accompanied by smaller increments in R(d) (12%) and net hepatic uptake of exogenous glucose (45%). In contrast, reducing hyperinsulinemia to basal levels, exenatide-increased total glucose turnover was completely abolished despite hyperglycemia (saline 2.9 ± 0.6 vs. exenatide 2.3 ± 0.3 mg · kg(−1) · min(−1), P = 0.29). CONCLUSIONS— Exenatide directly stimulates glucose turnover by enhancing insulin-mediated whole-body glucose disposal and increasing hepatic uptake of exogenous glucose, contributing to its overall action to lower postprandial glucose excursions.
format Text
id pubmed-2628608
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-26286082010-02-01 Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver Zheng, Dan Ionut, Viorica Mooradian, Vahe Stefanovski, Darko Bergman, Richard N. Diabetes Metabolism OBJECTIVE— Recent progress suggests that exenatide, a mimetic of glucagon-like peptide-1 (GLP-1), might lower glycemia independent of increased β-cell response or reduced gastrointestinal motility. We aimed to investigate whether exenatide stimulates glucose turnover directly in insulin-responsive tissues dependent or independent of insulinemia. RESEARCH DESIGN AND METHODS— An intraportal glucose infusion clamp was used in dogs to measure glucose turnover to encompass potent activation of the putative glucose/GLP-1 sensor in the porto-hepatic circulation with exenatide. The modified glucose clamp was performed in the presence of postprandial hyperinsulinemia and hyperglycemia with exenatide (20 μg) or saline injected at 0 min. Furthermore, the role of hyperglycemia versus hyperinsulinemia in exenatide-mediated glucose disposal was studied. RESULTS— With hyperinsulinemia and hyperglycemia, exenatide produced a significant increase in total glucose turnover by ∼30%, as indicated by portal glucose infusion rate (saline 15.9 ± 1.6 vs. exenatide 20.4 ± 2.1 mg · kg(−1) · min(−1), P < 0.001), resulting from increased whole-body glucose disposal (R(d), ∼20%) and increased net hepatic uptake of exogenous glucose (∼80%). Reducing systemic hyperglycemia to euglycemia, exenatide still increased total glucose turnover by ∼20% (saline 13.2 ± 1.9 vs. exenatide 15.6 ± 2.1 mg · kg(−1) · min(−1), P < 0.05) in the presence of hyperinsulinemia, accompanied by smaller increments in R(d) (12%) and net hepatic uptake of exogenous glucose (45%). In contrast, reducing hyperinsulinemia to basal levels, exenatide-increased total glucose turnover was completely abolished despite hyperglycemia (saline 2.9 ± 0.6 vs. exenatide 2.3 ± 0.3 mg · kg(−1) · min(−1), P = 0.29). CONCLUSIONS— Exenatide directly stimulates glucose turnover by enhancing insulin-mediated whole-body glucose disposal and increasing hepatic uptake of exogenous glucose, contributing to its overall action to lower postprandial glucose excursions. American Diabetes Association 2009-02 /pmc/articles/PMC2628608/ /pubmed/19011168 http://dx.doi.org/10.2337/db08-0875 Text en Copyright © 2009, American Diabetes Association Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Metabolism
Zheng, Dan
Ionut, Viorica
Mooradian, Vahe
Stefanovski, Darko
Bergman, Richard N.
Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
title Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
title_full Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
title_fullStr Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
title_full_unstemmed Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
title_short Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
title_sort exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver
topic Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628608/
https://www.ncbi.nlm.nih.gov/pubmed/19011168
http://dx.doi.org/10.2337/db08-0875
work_keys_str_mv AT zhengdan exenatidesensitizesinsulinmediatedwholebodyglucosedisposalandpromotesuptakeofexogenousglucosebytheliver
AT ionutviorica exenatidesensitizesinsulinmediatedwholebodyglucosedisposalandpromotesuptakeofexogenousglucosebytheliver
AT mooradianvahe exenatidesensitizesinsulinmediatedwholebodyglucosedisposalandpromotesuptakeofexogenousglucosebytheliver
AT stefanovskidarko exenatidesensitizesinsulinmediatedwholebodyglucosedisposalandpromotesuptakeofexogenousglucosebytheliver
AT bergmanrichardn exenatidesensitizesinsulinmediatedwholebodyglucosedisposalandpromotesuptakeofexogenousglucosebytheliver